MedTrace Logo

Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)

NCT02306109 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2018-08-07

No results posted yet for this study

Summary

ErmoSLA is a multicentric, randomized, controlled trial to compare effects of an "intensive" or "standard" motor rehabilitation treatment on motor disability in people with ALS

Conditions

Interventions

PROCEDURE

Standard motor rehabilitation treatment

Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up

PROCEDURE

Intensive motor rehabilitation treatment

Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up

Sponsors & Collaborators

  • University of Modena and Reggio Emilia

    collaborator OTHER

  • Azienda USL Reggio Emilia - IRCCS

    collaborator OTHER_GOV

  • S. Anna Hospital

    collaborator OTHER

  • Azienda Unità Sanitaria Locale Ferrara

    collaborator UNKNOWN

  • Azienda Unita' Sanitaria Locale Di Modena

    lead OTHER

Principal Investigators

  • Marco Vinceti, MD · Public Health Department, University of Modena and Reggio Emilia (IT)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-12-31
Completion
2018-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02306109 on ClinicalTrials.gov